

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) January 25, 2007

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

22-0760120

(Commission File Number)

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted principles (GAAP), as follows:

- Revenues. We present revenue growth rates at constant foreign exchange rates. We believe that presenting growth rates at constant foreign exchange rates allows investors to view the underlying operating results of BD and of its segments without the impact of fluctuations in foreign currency exchange rates, thereby facilitating comparisons to prior periods.
 - Selling and Administrative Expense. We present selling and administrative expense, both alone and as a percentage of revenues, for the first and second quarters of fiscal year 2006 and for the full 2006 fiscal year after excluding the impact of insurance settlements occurring during the period. These settlements caused reported selling and administrative expense to be lower than it otherwise would have been for the period in which they occurred, although these settlements are not considered part of ordinary operations by management. Accordingly, we believe that measures of selling and administrative expense that are adjusted for the effects of these settlements are more indicative of BD's underlying performance and assist investors in comparing BD's selling and administrative expense for the period to other periods.
 - Research and Development Expense. We present research and development expense, both alone and as a percentage of revenues, for the first quarter of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to the acquisition of TriPath Imaging, Inc. ("TriPath"), and for the second quarter of fiscal year 2006 and for the full 2006 fiscal year after excluding the impact of the in-process R&D charge relating to the acquisition of GeneOhm Sciences Inc. ("GeneOhm"). As these noncash charges are not considered by management to be part of ordinary operations and served to increase reported R&D expense for the period in which they were incurred, management believes that these adjusted measures are more indicative of BD's R&D activities. Management also presents these adjusted measures in order to assist investors in comparing BD's R&D expense for the period to other periods.
 - Operating Income. We present BD's operating income, both alone and as a percentage of revenues, for the first quarter of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to the TriPath acquisition. We also present BD's operating income, both alone and as a percentage of revenues, for the first quarter of fiscal year 2006 after excluding the impact of insurance settlements, and for the second quarter of fiscal year 2006 and for the full 2006 fiscal year after excluding the impact of insurance settlements and the in-process R&D charge relating to the GeneOhm acquisition. These items affected reported operating income for the period in which they occurred, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of operating income are more indicative of
-

BD's underlying performance, and also allow investors to better understand BD's comparative operating performance for the period presented.

- Income Taxes/Effective Tax Rate. We present income taxes and effective tax rate for the first and second quarters of fiscal year 2006 and the full 2006 fiscal year after excluding the impact of insurance settlements. These settlements caused reported income tax expense and effective tax rate to be higher than they otherwise would have been for the period in which they occurred, although these settlements are not considered part of ordinary operations by management. Management believes that these adjusted measures of income taxes are more indicative of BD's underlying results, and also allow investors to better understand BD's comparative income tax expense and tax rate for the period presented.
- Income from Continuing Operations. We present BD's income from continuing operations, both alone and as a percentage of revenues, for the first quarter of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to the TriPath acquisition. We also present BD's income from continuing operations, both alone and as a percentage of revenues, for the first quarter of fiscal year 2006 after excluding the impact of insurance settlements, and for the second quarter of fiscal year 2006 and for the full 2006 fiscal year after excluding the impact of these settlements and the in-process R&D charge relating to the GeneOhm acquisition. These items affected reported income from continuing operations for the period in which they occurred, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of income from continuing operations are more indicative of BD's underlying performance, and also allow investors to better understand BD's comparative income from continuing operations for the period presented.
- Earnings Per Share. We present earnings per share from continuing operations for the first quarter of fiscal year 2007 (and projected earnings per share from continuing operations for fiscal year 2007) after excluding the impact of the in-process R&D charge relating to the TriPath acquisition. This charge caused reported earnings per share for the period to be lower than it otherwise would have been, although the charge is not considered by management to be part of ordinary operations. We believe that a measure of earnings per share that is adjusted for the impact of this charge is more indicative of BD's underlying performance and also allows investors to more easily compare BD's results for the quarter to other periods.

We also present earnings per share from continuing operations for the first quarter of fiscal year 2006 after excluding the impact of insurance settlements, and for the second quarter of fiscal year 2006 and the full 2006 fiscal year after excluding the impact of these settlements and the in-process R&D charge relating to the GeneOhm acquisition. These items affected reported earnings per share for the period in which they occurred, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted

measures of earnings per share are more indicative of BD's underlying performance, and also allow investors to better understand BD's comparative performance for the period presented.

BD's management uses each of these non-GAAP measures in its own evaluation of BD's performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD's results.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD's financial results. Management believes the non-GAAP results provide a reasonable measure of BD's underlying performance before the effects of items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits. — Exhibit 99.1 Press release dated January 25, 2007, which is furnished pursuant to Item 2.02.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas
Dean J. Paranicas
Vice President, Corporate
Secretary and Public Policy

Date: January 25, 2007

INDEX TO EXHIBITS

**Exhibit
Number**

Description of Exhibits

99.1

Press release dated January 25, 2007, which is furnished pursuant to Item 2.02.

News Release



Contact:

Patricia A. Spinella, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369

BD ANNOUNCES RESULTS FOR FIRST FISCAL QUARTER

- First-quarter earnings per share from continuing operations, excluding specified item, increased 12% to 96 cents
- Raises guidance for full fiscal year 2007 earnings per share from continuing operations, excluding specified item, to a range of \$3.71 to \$3.77

Franklin Lakes, NJ (January 25, 2007) – BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of \$1.502 billion for the first fiscal quarter ended December 31, 2006, representing an increase of 8 percent over the prior year period. This quarter’s growth rate reflects the favorable impact on all segments from foreign currency translation, which overall is estimated to account for 2 percentage points of the growth.

“We are pleased with our strong start to fiscal 2007,” said Edward J. Ludwig, Chairman, President and Chief Executive Officer. “Increased sales of safety-engineered devices, prefillable drug delivery devices, and Biosciences products demonstrate the breadth of our growth drivers. Higher margin products and increased operating effectiveness continued to expand our operating profit margin. This performance has enabled us to increase the pace of our R&D spending while delivering double-digit earnings growth.”

TriPath Imaging Acquisition Completed

On December 20, 2006, BD completed its acquisition of TriPath Imaging, a maker of innovative solutions to improve the clinical management of cancer. The Company recorded an in-process research and development charge of \$115 million associated with the acquisition, which reduced diluted earnings per share from continuing operations by 45 cents in the first quarter (see Table 1 below).

BGM Product Line Sold

Following the receipt of an unsolicited offer during the quarter, the Company sold the blood glucose monitoring (BGM) product line for \$20 million, resulting in a pre-tax gain of \$15 million. Consequently, the results of operations of the BGM product line have been classified as discontinued operations for all quarters and years referred to in this release. Included in the attached financial tables are the Company's Consolidated Income Statements for fiscal year 2006, which reflect this classification change.

Analysis of First Quarter Fiscal Year 2007 and 2006 Earnings

Reported diluted earnings per share from continuing operations was 51 cents for the first quarter of fiscal 2007, which included the in-process research and development charge of 45 cents related to the TriPath acquisition. The following analysis of diluted earnings per share from continuing operations for the first quarter of fiscal 2007 and 2006 identifies specified items that affect comparability of results between periods. As illustrated in Table 1, diluted earnings per share from continuing operations, excluding specified item, for the first fiscal quarter of 2007 of 96 cents increased by 12 percent over diluted earnings per share from continuing operations, excluding specified items, of 86 cents for the first fiscal quarter of 2006.

(Table 1)	Three Months Ended December 31,		
	FY2007	FY2006	% Change
Diluted EPS from Continuing Operations:	\$ 0.51	\$ 0.87	-41%
Specified Items:			
In-Process Research and Development Charge ⁽¹⁾	0.45	—	
Insurance Settlement ⁽²⁾	—	(0.02)	
Rounding	—	0.01	
	<u>0.45</u>	<u>(0.01)</u>	
Diluted EPS from Continuing Operations Excluding Specified Items:	\$ 0.96	\$ 0.86	12%

⁽¹⁾ Represents the effect on diluted earnings per share from continuing operations of the in-process research and development charge recorded in the first quarter of fiscal 2007 related to the TriPath acquisition.

⁽²⁾ Represents the effect on diluted earnings per share from continuing operations related to proceeds received from insurance settlements regarding the Company's previously owned latex glove business.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$826 million, representing an increase of 10 percent over the prior year period. Strong sales of Pharmaceutical Systems products and safety-engineered devices contributed to growth.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$442 million, representing an increase of 2 percent over the prior year period. The Preanalytical Systems unit of the segment reported revenue growth of 8 percent due to strong sales of safety-engineered devices. Revenues in the Diagnostic Systems unit of the segment decreased 5 percent. The decline in sales of flu diagnostics tests, as compared to strong sales in the prior year period, more than offset double-digit growth from the BD ProbeTec™ ET and BD Phoenix™ instruments.

In the BD Biosciences segment, worldwide revenues for the quarter were \$233 million, representing an increase of 11 percent over the prior year period. Research instruments and reagent sales continued to be the primary growth contributors, driven by increased demand for research analyzers and clinical reagents.

Geographic Results

First quarter revenues in the U.S. were \$721 million, representing an increase of 9 percent over the prior year period. Revenues outside the U.S. were \$781 million, representing an increase of 7 percent over the prior year period, and reflect an estimated 4 percent favorable impact from foreign currency translation.

Fiscal 2007 Outlook for Full Year

The following analysis of estimated diluted earnings per share from continuing operations for the full fiscal year identifies specified items that affect the comparability of results between periods. As illustrated in Table 2, the Company estimates that diluted earnings per share from continuing operations, excluding specified item, for the full fiscal year 2007 will be in the \$3.71 to \$3.77 range, representing an increase of approximately 11 to 13 percent over diluted earnings per share from continuing operations, excluding specified items, of \$3.34 for the fiscal year 2006.

(Table 2)	Twelve Months Ended		
	September 30,		
	FY2007	FY2006	% Change
Diluted EPS from Continuing Operations:	\$ 3.26-\$3.32	\$ 3.18	3%-4%
Specified Items:			
In-Process Research and Development Charge ⁽¹⁾	0.45	0.21	
Insurance Settlements ⁽²⁾	—	(0.04)	
Rounding	—	(0.01)	
	0.45	0.16	
Diluted EPS from Continuing Operations Excluding Specified Items:	\$ 3.71-\$3.77	\$ 3.34	11%-13%

⁽¹⁾ Represents the effect on diluted earnings per share from continuing operations of the in-process research and development charge recorded in the first quarter of fiscal 2007 related to the TriPath acquisition and in the second quarter of fiscal 2006 related to the GeneOhm acquisition.

⁽²⁾ Represents the effect on diluted earnings per share from continuing operations related to proceeds received from insurance settlements regarding the Company's previously owned latex glove business.

Conference Call Information

A conference call regarding BD's first quarter results and its expectations for the full fiscal year will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (ET) Thursday, January 25, 2007. The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-866-427-6404 (domestic) and 1-203-369-0894 (international) through the close of business on February 1, 2007.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and the attached financial tables.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's

capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 27,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2007 Outlook for Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	Three Months Ended December 31,		% Change
	2006	2005	
REVENUES	\$ 1,501,526	\$ 1,393,845	7.7
Cost of products sold	708,933	665,946	6.5
Selling and administrative	384,084	349,027	10.0
Research and development	194,679	68,359	NM
TOTAL OPERATING COSTS AND EXPENSES	1,287,696	1,083,332	18.9
OPERATING INCOME	213,830	310,513	(31.1)
Interest income	16,114	14,671	9.8
Interest expense	(12,868)	(16,760)	(23.2)
Other expense, net	(2,368)	(1,163)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	214,708	307,261	(30.1)
Income tax provision	83,657	83,559	0.1
INCOME FROM CONTINUING OPERATIONS	131,051	223,702	(41.4)
INCOME/(LOSS) FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION/(BENEFIT) OF \$7,140 AND \$(3,550), RESPECTIVELY	11,828	(5,842)	NM
NET INCOME	\$ 142,879	\$ 217,860	(34.4)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 0.53	\$ 0.90	(41.1)
Income/(loss) from discontinued operations	\$ 0.05	\$ (0.02)	NM
Net income	\$ 0.58	\$ 0.88	(34.1)
Diluted:			
Income from continuing operations	\$ 0.51	\$ 0.87	(41.4)
Income/(loss) from discontinued operations	\$ 0.05	\$ (0.02)	NM
Net income	\$ 0.56	\$ 0.85	(34.1)
AVERAGE SHARES OUTSTANDING			
Basic	245,550	248,046	
Diluted	254,941	255,851	

NM - Not Meaningful

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Three Months Ended December 31,
(Unaudited; Amounts in thousands, except per-share data)

	2006		
	As Reported	Tri Path IPR&D (1)	Excluding Items
Research and Development as a % of Revenue	\$ 194,679 13.0%	\$ (114,739)	\$ 79,940 5.3%
Operating Income as a % of revenues	213,830 14.2%	114,739	328,569 21.9%
Income from continuing operations as a % of revenues	131,051 8.7%	114,739	245,790 16.4%
<u>Diluted earnings per share</u>			
Income from continuing operations	\$ 0.51	\$ 0.45	\$ 0.96

(1) Represents the in-process research and development ("IPR&D") charge related to the TriPath acquisition.

	2005		
	As Reported	Insurance Settlement (2)	Excluding Items
Selling and administrative as a % of revenues	\$ 349,027 25.0%	\$ 7,000	\$ 356,027 25.5%
Operating Income as a % of revenues	310,513 22.3%	(7,000)	303,513 21.8%
Income taxes effective tax rate	83,559 27.2%	(2,660)	80,899 26.9%
Income from continuing operations as a % of revenues	223,702 16.0%	(4,340)	219,362 15.7%
<u>Diluted earnings per share</u>			
Income from continuing operations (3)	\$ 0.87	\$ (0.02)	\$ 0.86

(2) Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business.

(3) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	Three Months Ended December 31,		
	2006	2005	% Change
<u>BD MEDICAL</u>			
United States	\$ 381,806	\$ 347,670	9.8
International	444,441	402,814	10.3
TOTAL	\$ 826,247	\$ 750,484	10.1
<u>BD DIAGNOSTICS</u>			
United States	\$ 242,899	\$ 224,731	8.1
International	199,501	209,387	(4.7)
TOTAL	\$ 442,400	\$ 434,118	1.9
<u>BD BIOSCIENCES</u>			
United States	\$ 95,921	\$ 89,670	7.0
International	136,958	119,573	14.5
TOTAL	\$ 232,879	209,243	11.3
<u>TOTAL REVENUES</u>			
United States	\$ 720,626	\$ 662,071	8.8
International	780,900	731,774	6.7
TOTAL	\$ 1,501,526	\$ 1,393,845	7.7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31,
(Unaudited; Amounts in thousands)

	United States		
	2006	2005	% Change
<u>BD MEDICAL</u>			
Medical Surgical Systems	\$ 242,301	\$ 222,266	9.0
Diabetes Care	90,492	91,488	(1.1)
Pharmaceutical Systems	42,899	28,400	51.1
Ophthalmic Systems	6,114	5,516	10.8
TOTAL	\$ 381,806	\$ 347,670	9.8
<u>BD DIAGNOSTICS</u>			
Preanalytical Systems	\$ 131,703	\$ 122,789	7.3
Diagnostic Systems (1)	111,196	101,942	9.1
TOTAL	\$ 242,899	\$ 224,731	8.1
<u>BD BIOSCIENCES</u>			
Discovery Labware (1)	\$ 34,088	\$ 32,056	6.3
Immunocytometry Systems	43,905	40,437	8.6
Pharmingén	17,928	17,177	4.4
TOTAL	\$ 95,921	\$ 89,670	7.0
TOTAL UNITED STATES	\$ 720,626	\$ 662,071	8.8

(1) Refer to page 9.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31, (continued)
(Unaudited; Amounts in thousands)

	International				
	2006	2005	Reported	% Change FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 225,450	\$ 205,897	9.5	6.2	3.3
Diabetes Care	78,194	71,992	8.6	5.1	3.5
Pharmaceutical Systems	130,041	115,363	12.7	7.9	4.8
Ophthalmic Systems	10,756	9,562	12.5	7.7	4.8
TOTAL	\$ 444,441	\$ 402,814	10.3	6.5	3.8
BD DIAGNOSTICS					
Preanalytical Systems	\$ 108,369	\$ 99,374	9.1	4.8	4.3
Diagnostic Systems (1)	91,132	110,013	(17.2)	(19.3)	2.1
TOTAL	\$ 199,501	\$ 209,387	(4.7)	(7.8)	3.1
BD BIOSCIENCES					
Discovery Labware (1)	\$ 29,800	\$ 27,389	8.8	5.7	3.1
Immunocytometry Systems	85,696	72,415	18.3	14.4	3.9
Pharmingén	21,462	19,769	8.6	5.2	3.4
TOTAL	\$ 136,958	\$ 119,573	14.5	10.9	3.6
TOTAL INTERNATIONAL	\$ 780,900	\$ 731,774	6.7	3.1	3.6

(1) Refer to page 9.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31, (continued)
(Unaudited; Amounts in thousands)

			Total		
	2006	2005	Reported	% Change FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 467,751	\$ 428,163	9.2	7.6	1.6
Diabetes Care	168,686	163,480	3.2	1.6	1.6
Pharmaceutical Systems	172,940	143,763	20.3	16.5	3.8
Ophthalmic Systems	16,870	15,078	11.9	8.9	3.0
TOTAL	\$ 826,247	750,484	10.1	8.0	2.1
BD DIAGNOSTICS					
Preanalytical Systems	\$ 240,072	\$ 222,163	8.1	6.2	1.9
Diagnostic Systems (1)	202,328	211,955	(4.5)	(5.6)	1.1
TOTAL	\$ 442,400	434,118	1.9	0.4	1.5
BD BIOSCIENCES					
Discovery Labware (1)	\$ 63,888	\$ 59,445	7.5	6.0	1.5
Immunocytometry Systems	129,601	112,852	14.8	12.3	2.5
Pharmingén	39,390	36,946	6.6	4.8	1.8
TOTAL	\$ 232,879	209,243	11.3	9.2	2.1
TOTAL REVENUES	\$ 1,501,526	\$ 1,393,845	7.7	5.8	1.9

(1) Refer to page 9.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS FISCAL 2006
Revised for Blood Glucose Monitoring Discontinued Operations
(Unaudited; Amounts in thousands, except per-share data)

	Quarter 1	Quarter 2	Quarter 3	Quarter 4	Year
REVENUES	\$ 1,393,845	\$ 1,424,209	\$ 1,457,347	\$ 1,462,616	\$ 5,738,017
Cost of products sold	665,946	698,766	719,515	709,038	2,793,265
Selling and administrative	349,027	346,322	374,565	378,252	1,448,166
Research and development	68,359	127,715	76,699	82,399	355,172
TOTAL OPERATING COSTS AND EXPENSES	1,083,332	1,172,803	1,170,779	1,169,689	4,596,603
OPERATING INCOME	310,513	251,406	286,568	292,927	1,141,414
Interest expense	(16,760)	(19,805)	(15,425)	(14,056)	(66,046)
Interest income	14,671	16,991	12,146	15,488	59,296
Other expense, net	(1,163)	(451)	(2,385)	(4,763)	(8,762)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	307,261	248,141	280,904	289,596	1,125,902
Income tax provision	83,559	84,683	69,834	72,716	310,792
INCOME FROM CONTINUING OPERATIONS	223,702	163,458	211,070	216,880	815,110
Loss from Discontinued Operations before Income Tax	(9,392)	(15,102)	(7,562)	(63,597)	(95,653)
Income Tax Benefit	(3,550)	(5,712)	(2,865)	(20,696)	(32,823)
NET LOSS FROM DISCONTINUED OPERATIONS	(5,842)	(9,390)	(4,697)	(42,901)	(62,830)
NET INCOME	\$ 217,860	\$ 154,068	\$ 206,373	\$ 173,979	\$ 752,280
EARNINGS PER SHARE					
Basic:					
Income from continuing operations	\$ 0.90	\$ 0.66	\$ 0.86	\$ 0.88	\$ 3.30
Loss from discontinued operations	\$ (0.02)	\$ (0.04)	\$ (0.02)	\$ (0.17)	\$ (0.25)
Net income (1)	\$ 0.88	\$ 0.62	\$ 0.84	\$ 0.71	\$ 3.04
Diluted:					
Income from continuing operations	\$ 0.87	\$ 0.63	\$ 0.83	\$ 0.85	\$ 3.18
Loss from discontinued operations (1)	\$ (0.02)	\$ (0.04)	\$ (0.02)	\$ (0.17)	\$ (0.24)
Net income (1)	\$ 0.85	\$ 0.60	\$ 0.81	\$ 0.68	\$ 2.93
AVERAGE SHARES OUTSTANDING					
Basic	248,046	248,088	246,633	245,522	247,067
Diluted	255,851	258,299	255,070	254,843	256,554

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
 REVISED SUPPLEMENTAL INFORMATION
 Revised for Blood Glucose Monitoring Discontinued Operations
 (Unaudited; Amounts in thousands, except per-share data)

	Second Quarter 2006 (1)			
	As Revised	Insurance Settlement (2)	GeneOhm IPR&D (3)	Excluding Items
Selling and administrative as a % of revenues	\$ 346,322 24.3%	\$ 10,000	\$ -	\$ 356,322 25.0%
Research and development as a % of revenues	127,715 9.0%	-	(53,300)	74,415 5.2%
Operating Income as a % of revenues	251,406 17.7%	(10,000)	53,300	294,706 20.7%
Income taxes effective tax rate	84,683 34.1%	(3,800)	-	80,883 27.8%
Income from continuing operations as a % of revenues	163,458 11.5%	(6,200)	53,300	210,558 14.8%
<u>Diluted earnings per share</u>				
Income from continuing operations (4)	\$ 0.63	\$ (0.02)	\$ 0.21	\$ 0.81

	Fiscal Year 2006 (1)			
	As Revised	Insurance Settlement (2)	GeneOhm IPR&D (3)	Excluding Items
Selling and administrative as a % of revenues	\$ 1,448,166 25.2%	\$ 17,000	-	\$ 1,465,166 25.5%
Research and development as a % of revenues	355,172 6.2%	-	(53,300)	301,872 5.3%
Operating Income as a % of revenues	1,141,414 19.9%	(17,000)	53,300	1,177,714 20.5%
Income taxes effective tax rate	310,792 27.6%	(6,460)	-	304,332 26.2%
Income from continuing operations as a % of revenues	815,110 14.2%	(10,540)	53,300	857,870 15.0%
<u>Diluted earnings per share</u>				
Income from continuing operations (4)	\$ 3.18	\$ (0.04)	\$ 0.21	\$ 3.34

(1) Revised supplemental information is not applicable for the third and fourth quarters of 2006.

(2) Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business.

(3) Represents the IPR&D charge related to the GeneOhm acquisition.

(4) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
SEGMENT RECLASSIFICATION FOR FISCAL 2006 REVENUES
(Unaudited; Amounts in thousands)

	United States (1)	International (1)	Total (1)
Quarter 1	\$ 4,357	\$ 5,379	\$ 9,736
Quarter 2	4,344	4,568	8,912
Quarter 3	4,389	5,085	9,474
Quarter 4	5,432	6,222	11,654
TOTAL	\$ 18,522	\$ 21,254	\$ 39,776

(1) Represents the impact of the reclassification of BD Advanced Bioprocessing revenues from the Diagnostic Systems unit of the BD Diagnostics Segment to the Discovery Labware unit of the BD Biosciences segment to conform to the current year presentation.